Search - tctmd.com

Displaying 1 - 20 of 150

Sort: Relevancy | Date

News Opinion CV Team Dispatch

December 2025 Dispatch for the CV Team

L.A. McKeown

December 23, 2025

Presentation TCT 2025

DAPT -Shock-AMI with use of Cangrelor

Presenter: Babar Basir

October 28, 2025

Presentation TCT India 2025

CANGRELOR New kid in anti-platelet therapy: where to prefer & what are its advantages

Presenter: S. Manoj

July 26, 2025

Presentation TCT 2024

TCT 299: Cangrelor Use in Acute Myocardial Infarction Patients Awaiting Coronary Artery Bypass Grafting

Presenter: Jennifer Rymer

October 29, 2024

Presentation TCT 2024

TCT 784: Gender Disparities in Cangrelor Outcomes for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Presenter: Waiel Abusnina

October 29, 2024

Presentation TCT 2024

TCT 174: High Bleeding Risk and Outcomes in Acute Coronary Syndrome After Percutaneous Coronary Intervention With Versus Without Cangrelor

Presenter: Patrick Creechan

October 28, 2024

Presentation TCT 2024

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

Presenter: Angelo Oliva

October 27, 2024

Presentation TCT 2024

TCT 1: Differential Outcomes in ST-Elevation and Non-ST Elevation Myocardial Infarction Outcomes After Percutaneous Coronary Intervention With Versus Without Cangrelor

Presenter: Andrew Hill

October 27, 2024

Presentation TCT 2024

TCT 1351: Cangrelor in a Challenging Scenario of Concomitant Ischemic Stroke, Pulmonary Embolism and STEMI

Presenter: Federico Oliveri

October 27, 2024

Presentation TCT 2024

TCT 238: Safety and Efficacy of Cangrelor: A Multicenter Nationwide Registry ARECA (Austrian Registry for Cangrelor Application)

Presenter: Guy Friedrich

October 27, 2024

Presentation TCT 2024

TCT 236: Bailout Use of Cangrelor During Percutaneous Coronary Intervention and Associated Inpatient Outcomes

Presenter: Abhishek Chaturvedi

October 27, 2024

News Daily News

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

Yael L. Maxwell

June 20, 2024

Presentation TCT 2023

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Presenter: Michael Savage

October 25, 2023

Presentation TCT 2023

Cangrelor Reduces Procedural Complications and Should Be the Default Strategy

Presenter: Jennifer Rymer

October 25, 2023

News Conference News ESC 2023

Avoid Using Prasugrel With Cangrelor During PCI, SWAP-6 Affirms

Todd Neale

August 22, 2023

News Conference News AHA 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Yael L. Maxwell

November 11, 2022

News Daily News

Still No Edge for Bivalirudin in VALIDATE-SWEDEHEART’s STEMI Patients

Shelley Wood

December 22, 2021

News

Tastes Like Ticagrelor: Mouth-Dissolving Pills Match Standard Ones in ACS

Yael L. Maxwell

July 13, 2021

News Daily News

ISAR-REACT 5: Subanalysis of PCI Patients Confirms Prasugrel Superiority

Yael L. Maxwell

July 01, 2021

Crushing Prasugrel Tabs Ups Platelet Inhibition Following Primary PCI

News Daily News

Crushed Prasugrel in the Ambulance Ups Platelet Inhibition in Primary PCI

Yael L. Maxwell

June 22, 2021

Advertisement

December 2025 Dispatch for the CV Team

DAPT -Shock-AMI with use of Cangrelor

CANGRELOR New kid in anti-platelet therapy: where to prefer & what are its advantages

TCT 299: Cangrelor Use in Acute Myocardial Infarction Patients Awaiting Coronary Artery Bypass Grafting

TCT 784: Gender Disparities in Cangrelor Outcomes for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

TCT 174: High Bleeding Risk and Outcomes in Acute Coronary Syndrome After Percutaneous Coronary Intervention With Versus Without Cangrelor

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

TCT 1: Differential Outcomes in ST-Elevation and Non-ST Elevation Myocardial Infarction Outcomes After Percutaneous Coronary Intervention With Versus Without Cangrelor

TCT 1351: Cangrelor in a Challenging Scenario of Concomitant Ischemic Stroke, Pulmonary Embolism and STEMI

TCT 238: Safety and Efficacy of Cangrelor: A Multicenter Nationwide Registry ARECA (Austrian Registry for Cangrelor Application)

TCT 236: Bailout Use of Cangrelor During Percutaneous Coronary Intervention and Associated Inpatient Outcomes

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Cangrelor Reduces Procedural Complications and Should Be the Default Strategy

Avoid Using Prasugrel With Cangrelor During PCI, SWAP-6 Affirms

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Still No Edge for Bivalirudin in VALIDATE-SWEDEHEART’s STEMI Patients

Tastes Like Ticagrelor: Mouth-Dissolving Pills Match Standard Ones in ACS

ISAR-REACT 5: Subanalysis of PCI Patients Confirms Prasugrel Superiority

Crushed Prasugrel in the Ambulance Ups Platelet Inhibition in Primary PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content